Grifols doses first patient in Phase 3 SIGMA trial of Gamunex-C in secondary immunodeficiency
GRFS•First patient dosed in Phase 3 SIGMA trial
Grifols dosed first patients in two Phase 3 trials aimed at expanding U.S. labels for immunoglobulin therapies GAMUNEX-C, XEMBIFY.
- SIGMA trial tests GAMUNEX-C with standard care to prevent infections in secondary immunodeficiency tied to hematologic cancers.
- XPERT trial evaluates whether subcutaneous XEMBIFY is non-inferior to GAMUNEX-C in CIDP, supporting a potential label expansion.
